Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

McGill University

$120,000.00

Identifying cell-cell interactions driving pathogenesis in RASopathy associated hypertrophic cardiomyopathy: towards novel therapeutic approaches

FY 2025-26

Summary
RASopathies are a group of rare congenital syndromes caused by the overactivation of a cellular signaling pathway called RAS/MAPK. Genetic defects in this pathway cause diseases affecting the brain, growth, and the heart. Hypertrophic cardiomyopathy, a disease where the heart walls become too thick, occurs in these patients particularly when the gene RAF1 is mutated, with the S257L mutation being the most frequent. Affected patients go on to develop chronic heart failure, and require heart surgery or even a transplant, which causes a lowered life expectancy and quality of life. Current treatments try to relieve symptoms, but don't reduce muscle thickening. My supervisor, Dr Andelfinger, has been successful is repurposing a cancer drug targeting the RAS/MAPK machinery, but treatment has yet to be fully optimized for all affected patients. The objective of my project is to try to identify new and better treatments. In the healthy heart, muscle cells, supporting cells and the cells lining the blood vessels constantly interact together to maintain the heart's normal function. In cases of heart disease, these interactions are altered. I will thus look at how different heart cells interact together in hypertrophic cardiomyopathy to identify which interactions are disrupted. I will use cells derived from patients, as well as a mouse model carrying the RAF1 S257L mutation to characterize cell behavior in the mutant models compared to healthy heart. Based on these observations, I will screen existing drugs that target these processes and reduce the hypertrophy.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
560182
Name
Medouni Anaïs
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Identifying cell-cell interactions driving pathogenesis in RASopathy associated hypertrophic cardiomyopathy: towards novel therapeutic approaches
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cardiac Microtissues; Cell-Cell Interactions; Genetic Mutations; Hypertrophic Cardiomyopathy; Induced Pluripotent Stem Cells; Mouse Model; Noonan Syndrome; Ras/Mapk Pathway; Rasopathies
Abstract
RASopathies are a group of rare congenital syndromes caused by the overactivation of a cellular signaling pathway called RAS/MAPK. Genetic defects in this pathway cause diseases affecting the brain, growth, and the heart. Hypertrophic cardiomyopathy, a disease where the heart walls become too thick, occurs in these patients particularly when the gene RAF1 is mutated, with the S257L mutation being the most frequent. Affected patients go on to develop chronic heart failure, and require heart surgery or even a transplant, which causes a lowered life expectancy and quality of life. Current treatments try to relieve symptoms, but don't reduce muscle thickening. My supervisor, Dr Andelfinger, has been successful is repurposing a cancer drug targeting the RAS/MAPK machinery, but treatment has yet to be fully optimized for all affected patients. The objective of my project is to try to identify new and better treatments. In the healthy heart, muscle cells, supporting cells and the cells lining the blood vessels constantly interact together to maintain the heart's normal function. In cases of heart disease, these interactions are altered. I will thus look at how different heart cells interact together in hypertrophic cardiomyopathy to identify which interactions are disrupted. I will use cells derived from patients, as well as a mouse model carrying the RAF1 S257L mutation to characterize cell behavior in the mutant models compared to healthy heart. Based on these observations, I will screen existing drugs that target these processes and reduce the hypertrophy.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Medouni, Anaïs
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~
McGill University - $120,000 Grant (2025-26) | Canada Spends